ALDOA and Crohn disease: Therefore, blockade of PGK1 or ALDOA should be considered as a potential immunotherapeutic strategy to boost AhR activation and ultimately control Th17 cell inflammatory potential while favoring the acquisition of suppressive features by these cells in Crohn’s disease.